Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Rare Disorders, Best Shot At Showing Clinical Benefit Is Post-Market –FDA

Executive Summary

FDA is acknowledging that clinical benefit for patients with rare conditions may best be verified through post-marketing trials, given the difficulty of conducting clinical trials in those populations

You may also be interested in...



Efficacy Hard To Prove In Orphan Diseases; Dyax Panel Questions Standards

One central theme of the recent advisory panel review for Dyax's hereditary angioedema therapy Kalbitor (ecallantide) was awareness that the challenges of studying an orphan disease make it difficult to provide conclusive evidence for a drug candidate

Efficacy Hard To Prove In Orphan Diseases; Dyax Panel Questions Standards

One central theme of the recent advisory panel review for Dyax's hereditary angioedema therapy Kalbitor (ecallantide) was awareness that the challenges of studying an orphan disease make it difficult to provide conclusive evidence for a drug candidate

GTC’s goat milk-derived ATryn approved

FDA approves the first therapeutic protein derived from a genetically engineered animal Feb. 6. GTC Biotherapeutics' ATryn (recombinant antithrombin III) received approval from both CBER and the Center for Veterinary Medicine to treat patients with the rare clotting disease hereditary antithrombin deficiency. ATryn is the first recombinant antithrombin approved in the U.S. The approval was also a first for CVM - this is the first genetically engineered animal construct to clear FDA, opening the door for future GE animal products in development. Although advisory committee members voted unanimously that a post-marketing study should be conducted to assess the risk/benefit profile after repeat dosing of ATryn, FDA did not mention any required studies in its press release (1"The Pink Sheet," Jan. 19, 2008, p. 27). GTC stated in its announcement that post-marketing studies will be performed to assess safety and immunogenicity after repeat dosing. ATryn should be available by the second quarter, GTC said

Related Content

Topics

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel